Pilot study to investigate whether oral phosphorus binders can reduce FGF23 levels and can influence vascular function as measured by pulse wave velocity in patiens with chronic kidney disease stage 3 (eGFR 30-60 ml/min/1,73 m2).

Pilot study to investigate whether oral phosphorus binders can reduce FGF23 levels and can influence vascular function as measured by pulse wave velocity in patiens with chronic kidney disease stage 3 (eGFR 30-60 ml/min/1,73 m2). - Effect van fosfaat verlaging op FGF23 en bloedvaten

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36731

Enrollment

Registered

2010-04-29

Start date

2010-01-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease CKD renal failure

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.patients with eGFR 30-60 ml/min/1,73 m2 2.serum phosphorus level 0,9 mmol/L 3.age >18 year 4.informed consent

Exclusion criteria

Exclusion criteria: 1. known allergy or intolerance for sevelamer-containing drugs 2. patients with heart failure 3. Use of phosphate binder therapy 4. Patients dependent on tube-feeding or those with malabsorption syndrome 5. rapidly deteriorating renal function 6. pregnant woman 7 patient with kidney transplantation

Design outcomes

Primary

Measure	Time frame
Serum FGF23 and phosphaturia before and after 8 weeks of treatment with sevelamer-carbonate and change in PWV	—

Secondary

Measure	Time frame
Pulse Wave Velocity measured before and after the treatment with Sevelamer.	—

Countries

Netherlands

Outcome results